Amid surging Covid-19 infections driven primarily by the Omicron variant comes news of the remarkable achievement by United States (US) surgeons who implanted a heart from a genetically modified pig into a 57-year-old recipient, David Bennett, who suffered from ventricular fibrillation (a kind of heart abnormality) and had advanced heart failure. The historic procedure performed on January 7 at the University of Maryland School of Medicine (UMSOM) is a major milestone in the field of xenotransplantation the exchange of organs among species, chiefly from pigs to humans.
According to Muhammad Mohiuddin, chief of the cardiac transplantation programme at UMSOM, Bennett urgently needed a transplant and was declared ineligible for a human organ; therefore, a decision was taken to try a xenograft from a pig. The transplant team obtained compassionate use authorisation from the US Food and Drug Administration, and the organ was made available by Revivicor, a US-based biotech company. The team already had years of experience with xenografting pig hearts into baboons with a fair degree of success and were well suited to try out the exercise in humans. In 2016, they had reported that a pig heart was kept functioning in a baboon for three years.
Xenotransplantation uses animals as a source of organs for replacement therapy in humans whose own natural organs have reached the end-stage of function. Since there is always a big gap between those needing a functioning organ (chiefly heart, kidney, liver, lungs and pancreas) and the availability of the same from humans, alternative sources of donor organs have long been an unmet need.
The most significant issue with using animals as a source of transplanted organs for humans is the spontaneous immunological rejection due to the occurrence of specific antibodies produced by the human host against certain sugars present on the surface of pig cells. These get recognised as foreign, leading to hyperacute rejection in which the recipient begins to reject the organ as soon as it is implanted.
In terms of evolution, pigs and humans are quite divergent, and the major challenges are both immunological and pathophysiological. The fundamental difference is while the human system expresses the well-known ABH blood group antigens, the pigs vascular endothelium expresses a unique protein called Galactose oligosaccharide or Gala1 or simply Gal. Humans are a natural knockout for this protein that quickly triggers anti-Gal antibodies against the transplanted organ.
In recent years, significant progress has been made to genetically modify the developing piglets, rendering their tissues and organs resistant to human immune response. The creation of Dolly the sheep as the first cloned animal in 1996 provided the much-needed stimulus to do so. In their effort to create a clinical-grade facility for raising engineered pigs, Revivicor scientists produced genetic changes in a total of 10 genes: Three in the pig and seven in humans. They successfully knocked out three genes from pigs that enable the enzymes to synthesise Gal sugars, and thus minimise the formation of anti-Gal antibodies.
Simultaneously, they engineered six genes in the human host with the aim of decreasing inflammation (two genes) and blood coagulation, thereby preventing blood vessel damage (two genes) and also silenced another two regulatory proteins that promote antibody response. The final step was something that they had learnt during baboon experimentation and this included knocking out the gene for a growth hormone that ensured that the pig organ remained matched in size with the patients chest and did not outgrow upon grafting.
Two weeks have passed and the pig heart is still functioning in Bennett, making the surgical feat a remarkable achievement. However, the question of whether we have reached the stage for regular use of pig organs for transplantation in humans is still open. More science is needed to determine which modifications are critical and perhaps inescapable. It is also not clear whether different modifications may be required for different organs. For example, could there be differences for kidney versus heart and likewise for other organs? Another major barrier with xenotransplantation is the possibility of endogenous retroviruses carried by pigs and these could create safety concerns.
The other question relates to the type and extent of immunosuppression needed for the recipient because of the possibility of excessive anti-organ-specific antibodies generated in the host. While the standard immunosuppressive regimens may or may not be effective, it would be necessary to investigate immunological tools to suppress the activity of antibody-forming B-cells and inhibit their cross-talk with helper T-cells that effectively coordinate the host immune response.
While there are several issues associated with xenotransplantation, both for the recipient and society at large, the first really successful pig-to-human heart transplant achieved through the meticulous use of the tools of genetic engineering represents a significant step forward in solving the problem of organ shortage, bringing hope to those in desperate need of a transplant.
Dr Narinder Kumar Mehra is an internationally acclaimed expert in transplant immunology and former Dean of the All India Institute of Medical Sciences, New Delhi
The views expressed are personal
See the article here:
Xenotransplantation and the future of medicine - Hindustan Times
- IOM not webcast today. Why Not? - November 8th, 2009 [November 8th, 2009]
- National Academies skeptical at Best. - November 8th, 2009 [November 8th, 2009]
- Some Confusion Exists - November 8th, 2009 [November 8th, 2009]
- Why DTC Genomics IS Medicine. - November 8th, 2009 [November 8th, 2009]
- First Mari, Now Linda. Who's next? - November 8th, 2009 [November 8th, 2009]
- Is it true? - November 8th, 2009 [November 8th, 2009]
- Re-Reviewing the National Academies - November 8th, 2009 [November 8th, 2009]
- The problem with nonclinicians....... - November 8th, 2009 [November 8th, 2009]
- Crazy Night of Emails to Government - November 8th, 2009 [November 8th, 2009]
- Adrienne Carlson's Personalized Medicine. - November 8th, 2009 [November 8th, 2009]
- Tell Me, How do you feel now? Sherpa's RX - November 8th, 2009 [November 8th, 2009]
- This Just In. 23andMe to go to GPs. I love my readers!! - November 8th, 2009 [November 8th, 2009]
- Sorry so long away - November 8th, 2009 [November 8th, 2009]
- 2D6 Rears its ugly head..... - November 8th, 2009 [November 8th, 2009]
- Ok, Fine, Back to Plavix - November 8th, 2009 [November 8th, 2009]
- Kaiser a protoype for Collins' Aim - November 8th, 2009 [November 8th, 2009]
- A few months late to the party.... - November 8th, 2009 [November 8th, 2009]
- Stated Another Way....... - November 8th, 2009 [November 8th, 2009]
- Excuse Me? Harvard and Navigenics? WTF? - November 8th, 2009 [November 8th, 2009]
- Follow up to Yesterday's WTF? Harvard, Navi? and Pfizer??? - November 8th, 2009 [November 8th, 2009]
- Did you get your kit? Thanks Dr. Rob from MedCo - November 8th, 2009 [November 8th, 2009]
- Gluco...Wha? Parkinson's Disease and Glucocerebrosidase mutations. - November 8th, 2009 [November 8th, 2009]
- Away and now back, What did I miss???? 23andme layoffs? Selling Genomes for cheap up next! - November 8th, 2009 [November 8th, 2009]
- Change IS Needed. I agree with William, sometimes. - November 8th, 2009 [November 8th, 2009]
- Good Enough Science? Apparently so at 23andme - November 8th, 2009 [November 8th, 2009]
- Long QT Syndrome, location matters - December 13th, 2009 [December 13th, 2009]
- Congratulations Generation Health. Nice pick up! - December 13th, 2009 [December 13th, 2009]
- An argument 23andSerge can't win...23andme but not medicine - December 13th, 2009 [December 13th, 2009]
- Stop. Breathe. Repeat. An analysis of the direction of DTC Genomics Field. - December 13th, 2009 [December 13th, 2009]
- Hey DTC genomics, Stay Private, Stay Alive, Go Public and Die - December 13th, 2009 [December 13th, 2009]
- You can't have it both way. Either scared your genome is sold off or not. - December 13th, 2009 [December 13th, 2009]
- 15 Days Away Gives Time for Perspective. - December 13th, 2009 [December 13th, 2009]
- What about the SACGHS registry? Another missed opportunity? - December 13th, 2009 [December 13th, 2009]
- AJHG is in and my Favorite Muin is in it! But He Is NOT the Father! - December 13th, 2009 [December 13th, 2009]
- Navigenics for 23andMe prices? - December 18th, 2009 [December 18th, 2009]
- Lp(a) Maybe there's something there that wasn't there before? - December 24th, 2009 [December 24th, 2009]
- Another Year, Another Bankruptcy - December 31st, 2009 [December 31st, 2009]
- 5 Technologies going bye bye in this decade? - January 6th, 2010 [January 6th, 2010]
- Hackers, HITECH and HIPAA in DTC Genomics, Oh My! - January 7th, 2010 [January 7th, 2010]
- Personal Genomics Flop.....big Belly Flop! - January 8th, 2010 [January 8th, 2010]
- Gotta Love It. Even the daycare....... - January 11th, 2010 [January 11th, 2010]
- Congratulations Navigenics. You ARE a clinical lab! Uh-Oh... - January 12th, 2010 [January 12th, 2010]
- CETP, Jewish Centenarians and Alzheimers - January 14th, 2010 [January 14th, 2010]
- Enter the "Not" DTC Genomics Rep - January 17th, 2010 [January 17th, 2010]
- Why Dr. Vanier's Navigenics appointment is good for PM - January 22nd, 2010 [January 22nd, 2010]
- Holy Crap! MedCo Follows in CVS footsteps - February 3rd, 2010 [February 3rd, 2010]
- FDA, Warfarin, still not as sexy to me. - February 5th, 2010 [February 5th, 2010]
- Hype, Hype, Hype from a single study. - February 11th, 2010 [February 11th, 2010]
- I love my readers, even Renata M! - February 17th, 2010 [February 17th, 2010]
- How can insurers use DTC genomics to profile? - February 17th, 2010 [February 17th, 2010]
- 9p21.....ahem. Paynter et.al. Smackdown. Again. - February 18th, 2010 [February 18th, 2010]
- Hey! It's Pete Hulick! Are you Going to GET? - February 19th, 2010 [February 19th, 2010]
- I was wrong......AHEM - February 28th, 2010 [February 28th, 2010]
- G2C2, finally a tool for genomic education! - March 2nd, 2010 [March 2nd, 2010]
- Just 4 million? What 23andMe is worth. - March 5th, 2010 [March 5th, 2010]
- What a difference a year makes - March 9th, 2010 [March 9th, 2010]
- ........DTC Genomic Medicine? - March 12th, 2010 [March 12th, 2010]
- The FDA, 2c19 and the ACC - March 13th, 2010 [March 13th, 2010]
- The problem with Comparative Whole Genomics...... - March 13th, 2010 [March 13th, 2010]
- BRCA testing by 23andME is the same as Myriad Genetics. - March 15th, 2010 [March 15th, 2010]
- The Argument Against DTC Genomics Marketing and such - March 16th, 2010 [March 16th, 2010]
- A moment of Clarity. Some DTCG is not bad. - March 18th, 2010 [March 18th, 2010]
- SNPs for breast cancer risk? It Depends. - March 18th, 2010 [March 18th, 2010]
- How can MDVIP use Navigenics Test for Medicine? - March 18th, 2010 [March 18th, 2010]
- Why did P&G invest in Navigenics? - March 23rd, 2010 [March 23rd, 2010]
- PGx in DTCG? Doesn't stand up to Useful testing. - March 25th, 2010 [March 25th, 2010]
- End of Gene Patents? - March 29th, 2010 [March 29th, 2010]
- Sherpa Accepting Chief Medical Officership - April 3rd, 2010 [April 3rd, 2010]
- The Rumors of My Death........ - April 20th, 2010 [April 20th, 2010]
- Happy DNA Day! - April 25th, 2010 [April 25th, 2010]
- 99 USD, DNA day and patient letters - April 25th, 2010 [April 25th, 2010]
- 2C19, Navigenics and Clinical Reality. - May 1st, 2010 [May 1st, 2010]
- Coriell Personalized Medicine Collaborative rising - May 7th, 2010 [May 7th, 2010]
- Personal Genomes in Clinical Care. Quake paper is a waste! - May 11th, 2010 [May 11th, 2010]
- Personal Genomes in Clinical Care. Quake paper Falls Short! - May 13th, 2010 [May 13th, 2010]
- Last post edited by Drew - May 13th, 2010 [May 13th, 2010]
- GateKeeper? FCUK U! - May 13th, 2010 [May 13th, 2010]
- GateKeeper? F! U! - May 15th, 2010 [May 15th, 2010]
- Potential of genomic medicine, LOST - May 19th, 2010 [May 19th, 2010]
- How Bad Can a House Investigation be for DTC Genomics? - May 20th, 2010 [May 20th, 2010]